Pharmaceutical companies sued the food and Drug Administration follow-up no filing-女f4

Pharmaceutical companies sued the food and Drug Administration follow-up: not filing to the food and Drug Administration for pharmaceutical companies shall file the Guangzhou daily news (reporter Tu Duanyu) the Bureau’s official website will respond to solve electronic supervision code problems before the Spring Festival make the raise a Babel of criticism of "mingaoguan" — Hunan Yang days and pharmacy enterprise group limited to the identity of the plaintiff, sued the state food the Drug Administration commissioned Ali healthy operation of drug electronic supervision code regarding the lack of legitimacy, the reporter was informed yesterday, the Beijing first intermediate people’s court made the ruling shows that the center of the case is a reason not to file claims in court: the scope of administrative litigation. And the food and drug administration also responded in its official website, said: "will properly solve the electronic regulatory code and other historical issues". It is reported that in the complaint, a day and responsible person made three claims, requesting confirmation of administrative acts of the State Food and drug administration to enforce the electronic supervision code law; decree of the State Food and drug administration to immediately stop the illegal act; the State Food and Drug Administration formulated the "drug quality management standards" of drug electronic supervision the terms of the legitimacy review. According to the understanding, the Beijing intermediate people’s court deems that the State Food and Drug Administration revised the "drug quality management standards" belongs to the rules, implementation of electronic monitoring code is the behavior rules, universal binding, so the plaintiff requested confirmation of administrative acts of the State Food and drug administration the implementation of electronic monitoring code and stop the illegal behavior the request does not belong to the administrative litigation case by the people’s court range. The reporter found that the food and drug administration has hung out the relevant response in the official home page eye-catching position, said it held a special forum to listen to the views of all parties. The Bureau said: "according to the general office of the State Council issued in December 2015" on accelerating the construction of traceability system for important products "requirements, establish and improve food and drug traceability management system is the main responsibility of the food and drug production enterprises, all food and drug production enterprises must be on the production and sales of products to achieve the source to be investigated, to to catch, and bear all legal liability. The food and drug administration can give necessary guidance." But the last statement also said: "for historical issues since 2006, the former State Food and Drug Administration commissioned the construction and operation of enterprise electronic drug supervision system, opinions on issues related to the implementation of part of the enterprise in the process of electronic monitoring code, food and drug supervision administration is seriously study and will make a deal." Enter Sina Financial shares] discussion

药企状告食药监总局后续:不予立案   药企告食药监总局不予立案   广州日报讯 (记者涂端玉)   该局官网回应将解决电子监管码问题   春节前闹得沸沸扬扬的“民告官”――湖南养天和大药房企业集团有限公司以原告身份,起诉国家食药监总局认为其委托阿里健康运营药品电子监管码缺少合法性一事,昨日记者获悉,北京市第一中级人民法院作出行政裁定书显示,该院对此案不予立案的理由是:诉讼请求不在法院行政诉讼的受案范围。而食药监总局也在其官网回应表示:“将妥善解决电子监管码等历史遗留问题”。   据悉,在起诉状中,养天和负责人提出三点诉讼请求,请求确认国家食药监总局强制推行电子监管码的行政行为违法;判令国家食药监总局立即停止违法行为;对国家食药监总局制定的《药品经营质量管理规范》中关于药品电子监管的条款之合法性进行审查。而据了解,北京一中院审查认为,国家食药监总局修订的《药品经营质量管理规范》属于规章,推行电子监管码的行为是该规章规定的,具有普遍约束力,故原告要求确认国家食药监总局推行电子监管码的行政行为违法并停止该行为的请求,不属于人民法院行政诉讼的受案范围。   而记者发现,食药监总局已在官网首页醒目位置挂出相关回应,称就此专门召开了座谈会听取各方意见。该局表示:“根据国务院办公厅2015年12月印发的《关于加快推进重要产品追溯体系建设的意见》要求,建立健全食品药品追溯管理制度是食品药品生产经营企业的主体责任,所有食品药品生产经营企业都必须对其生产和销售的产品做到来源可查、去向可追,并承担全部法律责任。食品药品监管部门可以给予必要指导。”   但其最后也表态称:“对2006年以来原国家食品药品监督管理局委托有关企业建设运营药品电子监管系统的历史遗留问题,对部分企业提出的实施电子监管码过程中有关问题的意见,食品药品监管总局正在认真研究并将作出妥善处理。” 进入【新浪财经股吧】讨论相关的主题文章: